from New York Times Nov 14, 2006
To Catch a Deadly Germ
By BETSY McCAUGHEY Originally Published: November 14, 2006
WHAT kills more than five times as many Americans as AIDS?
Hospital infections, which account for an estimated 100,000 deaths every year.
Yet the Centers for Disease Control and Prevention, which are calling for voluntary blood testing of all patients to stem the spread of AIDS, have chosen not to recommend a test that is essential to stop the spread of another killer sweeping through our nation’s hospitals: MRSA, or methicillin-resistant Staphylococcus aureus. The CDC guidelines to prevent hospital infections, released last month, conspicuously omit universal testing of patients for MRSAThat’s unfortunate. Research shows that the only way to prevent MRSA infections is to identify which patients bring the bacteria into the hospital. The MRSA test costs no more than the HIV test and is less invasive, a simple nasal or skin swab.
Staph bacteria are the most prevalent infection-causing germs in most hospitals, and increasingly these infections cannot be cured with ordinary antibiotics. Sixty percent of staph infections are now drug resistant (that is, MRSA), up from 2 percent in 1974.
Some people carry MRSA germs in their noses or on their skin without realizing it. The bacteria do not cause infection unless they get inside the body – usually via a catheter, a ventilator, or an incision or other open wound. Once admitted to a hospital, these patients shed the germs on bedrails, wheelchairs, stethoscopes and other surfaces, where MRSA can live for many hours.
Doctors and other caregivers who lean over an MRSA-positive patient often pick up the germ on their hands, gloves or lab coats and carry it along to their next patient.
The blood-pressure cuffs that nurses wrap around patients’ bare arms frequently carry live bacteria, including MRSA In a recent study at a French teaching hospital, 77 percent of blood-pressure cuffs wheeled from room to room were contaminated. Another study linked contaminated blood-pressure cuffs to several infected infants in the nursery at the University of Iowa hospital.
Among developed nations, the United States has one of the worst records of curbing drug-resistant infections, according to the Sentry Antimicrobial Surveillance Program, an international effort to monitor drug-resistant germs. In this country, MRSA hospital infections increased 32-fold from 1976 to 2003, according to the CDC
In the 1980s, Denmark, Finland and the Netherlands faced similarly soaring rates of MRSA, but nearly eradicated it. How? By screening patients and requiring health care workers treating patients with MRSA to wear gowns and gloves and use dedicated equipment to prevent the spread. The Dutch called their strategy “search and destroy.”
A growing number of hospitals in the United States have proved that such precautions work here, too. Recently, a pilot program using screening at Presbyterian University Hospital, in Pittsburgh, reduced MRSA infections by 90 percent. At a Yale-affiliated hospital in New Haven, screening reduced MRSA infections in intensive care by two-thirds.
And a recently completed nine-year study at the Brigham and Women’s Hospital, in Boston, found that screening led to a 75 percent drop in MRSA bloodstream infections among intensive-care patients and a 67 percent decline throughout the hospital.
Some public health advocates recommend screening only “high-risk” patients – those who recently have been hospitalized, live in nursing homes or have kidney disease. Partial screening is somewhat effective, but universal screening prevents the most infections.
Can hospitals afford to screen for MRSA? They cannot afford not to. Infections wipe out hospital profits. When a patient develops an infection and has to spend many additional weeks hospitalized, Medicare does not pay for most of that additional care.
Treating hospital infections costs an estimated $30.5 billion a year in the United States. Prevention, on the other hand, is inexpensive and requires no capital outlays. A pilot program at the University of Pittsburgh found that screening tests, gowns and other precautions cost only $35,000 a year, and saved more than $800,000 a year in infection costs. A review of similar cost analyses, published in The Lancet in September, concluded that MRSA screening increases hospital profits – as it saves lives.
Yet, for a decade, the CDC has rebuffed calls for screening, most recently from a committee of the Society for Healthcare Epidemiologists of America. CDC officials claim that more research is needed to prove the benefits of screening. More research cannot hurt, but we know enough already to move ahead. Some hospitals are leading the way, including Evanston Northwestern, in Illinois; the Veterans Affairs medical centers; New England Baptist Hospital, in Boston; and Johns Hopkins Hospital, in Baltimore.
The CDC’s lax guidelines give many other hospitals an excuse to do too little. Every year of delay costs thousands of lives and billions of dollars.
Betsy McCaughey, a former lieutenant governor of New York, is the founder of the Committee to Reduce Infection Deaths.
Prevent the Spread of MRSA
Hand Sanitizers are the first line of defense, but they must be effective against MRSA! Use Viraguard Products… Efffective against MRSA..
Buy Viraguard MRSA Hand Santizer
or choose PureGreen24 green MRSA disinfectant
What is Viraguard?
VIRAGUARD ANTISEPTIC HAND Gel
- Highly Antiseptic
- Won’t Dry Out Hands and Skin
- Citrus Scent
- Meets CDC Guidelines for Hand Hygiene in Healthcare Settings
- FDA Drug Listed
- Kills Hepatitis A, B and C
VIRAGUARD Antiseptic Hand Gel are your first line of defense against a broad-spectrum of gram-negative and gram-positive bacteria, drug resistant strains such as VRE and MRSA, tuberculosis, viruses including HIV and Herpes, and common skin fungi. The patented formulation contains Isopropyl Alcohol 75% v/v and a hand-protecting emollient and humectant that won’t dry your skin even with repeated useContains the Concentration of Isopropyl Alcohol (Isopropyl Alcohol 75% v/v) Most Needed by Health-Care Workers and First Responders.
Viraguard hand sanitizing products contain 75% Isopropyl Alcohol combined with emollients in our patented formula. Isopropyl Alcohol, long recognized in Europe as the reference standard for hand hygiene has now been recognized by the CDC as a suitable decontaminant for hands that are not visibly soiled 1. Viraguard also meets the OSHA Bloodborne Pathogen Standard 2.
Viraguard antiseptic hand sprays, gel and wipes was formulated and designed for use by health care professionals who appreciate the broad spectrum efficacy of Viraguard against bacteria, TB, Fungi and viruses as demonstrated thought in-vitro testing.